Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain.

Woo TD, Oka K, Takahashi M, Hojo F, Osaki T, Hanawa T, Kurata S, Yonezawa H, Kamiya S.

J Med Microbiol. 2011 Nov;60(Pt 11):1617-25. doi: 10.1099/jmm.0.033423-0. Epub 2011 Jun 23.

PMID:
21700738
2.

In vitro inhibition of Clostridium difficile and Clostridium perfringens by commercial probiotic strains.

Schoster A, Kokotovic B, Permin A, Pedersen PD, Dal Bello F, Guardabassi L.

Anaerobe. 2013 Apr;20:36-41. doi: 10.1016/j.anaerobe.2013.02.006. Epub 2013 Mar 5.

PMID:
23471038
3.

Co-culture with potentially probiotic microorganisms antagonises virulence factors of Clostridium difficile in vitro.

Trejo FM, Pérez PF, De Antoni GL.

Antonie Van Leeuwenhoek. 2010 Jun;98(1):19-29. doi: 10.1007/s10482-010-9424-6. Epub 2010 Mar 16.

PMID:
20232250
4.

The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O157:H7 infection in mice.

Takahashi M, Taguchi H, Yamaguchi H, Osaki T, Komatsu A, Kamiya S.

FEMS Immunol Med Microbiol. 2004 Jul 1;41(3):219-26.

5.

Detection of Clostridium difficile toxin A by reversed passive latex agglutination.

Toma C, Nakamura S, Kamiya S, Nakasone N, Iwanaga M.

Microbiol Immunol. 1999;43(8):737-42.

6.

Safety assessment of the Clostridium butyricum MIYAIRI 588® probiotic strain including evaluation of antimicrobial sensitivity and presence of Clostridium toxin genes in vitro and teratogenicity in vivo.

Isa K, Oka K, Beauchamp N, Sato M, Wada K, Ohtani K, Nakanishi S, McCartney E, Tanaka M, Shimizu T, Kamiya S, Kruger C, Takahashi M.

Hum Exp Toxicol. 2016 Aug;35(8):818-32. doi: 10.1177/0960327115607372. Epub 2015 Oct 5.

PMID:
26437792
7.
8.

Evaluation of real-time PCR and conventional diagnostic methods for the detection of Clostridium difficile-associated diarrhoea in a prospective multicentre study.

van den Berg RJ, Vaessen N, Endtz HP, Schülin T, van der Vorm ER, Kuijper EJ.

J Med Microbiol. 2007 Jan;56(Pt 1):36-42.

PMID:
17172514
9.

In vitro inhibition of Clostridium difficile by commercial probiotics: A microcalorimetric study.

Fredua-Agyeman M, Stapleton P, Basit AW, Beezer AE, Gaisford S.

Int J Pharm. 2017 Jan 30;517(1-2):96-103. doi: 10.1016/j.ijpharm.2016.12.005. Epub 2016 Dec 5.

PMID:
27923699
10.
11.

Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR.

Kato H, Kato N, Watanabe K, Iwai N, Nakamura H, Yamamoto T, Suzuki K, Kim SM, Chong Y, Wasito EB.

J Clin Microbiol. 1998 Aug;36(8):2178-82.

12.

Efficacy of Clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy in relation to changes in the intestinal microbiota.

Imase K, Takahashi M, Tanaka A, Tokunaga K, Sugano H, Tanaka M, Ishida H, Kamiya S, Takahashi S.

Microbiol Immunol. 2008 Mar;52(3):156-61. doi: 10.1111/j.1348-0421.2008.00026.x.

13.

Kefir-isolated Lactococcus lactis subsp. lactis inhibits the cytotoxic effect of Clostridium difficile in vitro.

Bolla PA, Carasi P, Serradell Mde L, De Antoni GL.

J Dairy Res. 2013 Feb;80(1):96-102. doi: 10.1017/S0022029912000623. Epub 2012 Dec 10.

PMID:
23217732
14.

Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro.

Lima AA, Lyerly DM, Wilkins TD, Innes DJ, Guerrant RL.

Infect Immun. 1988 Mar;56(3):582-8.

15.

Nosocomial outbreak of Clostridium difficile-associated diarrhoea due to a clindamycin-resistant enterotoxin A-negative strain.

Kuijper EJ, de Weerdt J, Kato H, Kato N, van Dam AP, van der Vorm ER, Weel J, van Rheenen C, Dankert J.

Eur J Clin Microbiol Infect Dis. 2001 Aug;20(8):528-34.

PMID:
11681431
16.

Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model.

Freeman J, Baines SD, Saxton K, Wilcox MH.

J Antimicrob Chemother. 2007 Jul;60(1):83-91. Epub 2007 May 5.

PMID:
17483547
17.

Effects of orally administered Clostridium butyricum MIYAIRI 588 on mucosal immunity in mice.

Murayama T, Mita N, Tanaka M, Kitajo T, Asano T, Mizuochi K, Kaneko K.

Vet Immunol Immunopathol. 1995 Oct;48(3-4):333-42.

PMID:
8578691
18.

[Investigation of toxin genes of Clostridium difficile strains isolated from hospitalized patients with diarrhoea at Marmara University Hospital].

Deniz U, Ulger N, Aksu B, Karavuş M, Söyletir G.

Mikrobiyol Bul. 2011 Jan;45(1):1-10. Turkish.

PMID:
21341153
19.

CcpA-mediated repression of Clostridium difficile toxin gene expression.

Antunes A, Martin-Verstraete I, Dupuy B.

Mol Microbiol. 2011 Feb;79(4):882-99. doi: 10.1111/j.1365-2958.2010.07495.x. Epub 2010 Dec 28.

20.

Effect of sub-MIC concentrations of metronidazole, vancomycin, clindamycin and linezolid on toxin gene transcription and production in Clostridium difficile.

Gerber M, Walch C, Löffler B, Tischendorf K, Reischl U, Ackermann G.

J Med Microbiol. 2008 Jun;57(Pt 6):776-83. doi: 10.1099/jmm.0.47739-0.

PMID:
18480337

Supplemental Content

Support Center